ALUMIS (ALMS) Company Report

Alumis Inc. reported a net loss of $110.8 million and $2.1 million in collaboration revenue for the third quarter ended September 30, 2025.
As of September 30, 2025, the company's cash, cash equivalents, and marketable securities totaled $377.7 million, which is projected to support operations into 2027.
The company anticipates key clinical data readouts, including topline Phase 3 ONWARD data for envudeucitinib in moderate-to-severe plaque psoriasis early in Q1 2026, and topline Phase 2b LUMUS data in systemic lupus erythematosus in Q3 2026.

Nov 13, 2025, 9:17 PM

Alumis Outlines Key 2026 Clinical Milestones and Partnership Strategy

ALMS

New Projects/Investments

Guidance Update

Alumis anticipates significant clinical trial readouts in 2026, including Phase 3 psoriasis data for Envudeucitinib in early Q1 2026 and Phase 2b lupus data for Envudeucitinib in Q3 2026.
The company's second TYK2 inhibitor, A-005, is expected to enter Phase 2 in MS in the first half of 2026.
Alumis reported a cash position of more than $480 million as of Q2, providing a cash runway into 2027.
The company plans to partner Envudeucitinib to maximize its value, especially if the psoriasis Phase 3 results are positive.

Nov 12, 2025, 7:00 PM

Alumis Provides Updates on Clinical Pipeline and Financial Position

ALMS

New Projects/Investments

Guidance Update

Alumis reported a strong balance sheet with over $480 million in cash at the end of Q2 2025, projecting a cash runway into 2027.
Key clinical milestones for the lead asset, Envutuzitinib (TYK2 inhibitor), include phase 3 psoriasis data in early Q1 2026 (16- and 24-week results) and phase 2b lupus data in Q3 2026. The lupus trial is designed as pivotal.
The company aims for Envutuzitinib to achieve 60-70% PASI 90 in psoriasis to be highly competitive and plans to partner the asset.
Alumis's brain-penetrant TYK2 molecule, A-005, is set to begin a Phase 2 study in Multiple Sclerosis (MS) in the first half of 2026.

Nov 11, 2025, 6:30 PM

Alumis Provides Update on Clinical Pipeline and Financial Runway

ALMS

New Projects/Investments

M&A

Alumis anticipates Phase 3 psoriasis data for its lead asset, ESK-001, in early Q1 2026, with Phase 2b lupus data expected in Q3 2026.
The company's cash runway is projected to extend into 2027, supported by the Acceleron merger, covering key clinical readouts.
ESK-001 is positioned as a differentiated TYK2 inhibitor, capable of achieving high target inhibition without the dose-reduction issues observed with some other molecules.
Alumis is also advancing A-005, a brain-penetrant TYK2, into Phase 2 for MS, and has lonigutamab and an IRF5 program with Phase 1 data anticipated in 2026.

Sep 16, 2025, 4:30 PM

Alumis Inc. Provides Updates on Clinical Pipeline and Financial Position

ALMS

New Projects/Investments

Guidance Update

Product Launch

Alumis Inc. expects Phase 3 psoriasis read-out in early Q1 next year and pivotal Phase 2b lupus read-out in Q3 next year. The company plans to file for psoriasis in 2026.
The company reported $486 million in cash and cash equivalents at the end of the second quarter, providing a cash runway into 2027. R&D expenses are expected to significantly decrease in the second half of this year.
Alumis is unlikely to launch its drug, Envutucitinib (Envu), globally independently and is considering partnerships. A once-a-day formulation of Envu is planned within the first year of launch.
A Phase 2 trial for A-005, a brain-penetrant TIK2 inhibitor, in MS is set to begin in the first half of next year.

Sep 3, 2025, 2:52 PM

Earnings Transcripts

Quarterly earnings call transcripts for ALUMIS.

Get instant answers from SEC filings, earnings calls & more

Get instant analysis when filings drop